Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus delbrueckii
- Development stage
- Phase 1
- Lead developer
- Iranian Research Organization for Science and Technology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus delbrueckii is a species of probiotic bacteria with immunomodulatory properties. [1, 6] An ex vivo study investigating its effects on peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE) found that L. delbrueckii significantly increased the gene expression of the regulatory T-cell transcription factor FOXP3 and the anti-inflammatory cytokines Interleukin-10 (IL-10) and Interleukin-2 (IL-2). [8] It also showed a trend towards decreasing the expression of the pro-inflammatory cytokine IL-6. These findings suggest that L. delbrueckii has a tolerogenic function and may be a candidate for developing complementary therapies for autoimmune diseases like SLE. [2, 4] It has also been studied in a clinical trial for Irritable Bowel Syndrome (IBS). [1, 5]
- Brand names
- Dingjunshuang
- Other names
- L. delbrueckii
02
Targets
IL10 (Interleukin-10)FOXP3 (Forkhead box protein P3)IL-6 (Interleukin 6)IL-2 (Interleukin 2)
Beyond the preview
Go deeper on lactobacillus delbrueckii.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus delbrueckii.